BEAM News and Press, Beam Therapeutics Inc. From 04/23/24

2024-04-23 21:48:22 ET Summary Beam Therapeutics is a biotech firm focused on developing precision genetic treatments using base editing technology. The company has secured $675 million in upfront payments from agreements with Pfizer, Apellis, Verve, and Sana. Collaboration ag...

2024-04-19 03:54:17 ET Summary ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. The top three holdings in the portfolio are Coinbase Global, Tesla, and Block, making up around 20% of the assets. ARK Invest ...

2024-04-02 20:15:01 ET Citigroup analyst issues BUY recommendation for BEAM on April 2, 2024 07:14PM ET. The previous analyst recommendation was Buy. BEAM was trading at $30.55 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2024-04-02 11:36:00 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...

2024-04-02 07:34:50 ET More on Verve Therapeutics Verve's Proof-Of-Concept Data Doesn't Inspire Confidence Vectoring In On Verve Therapeutics Seeking Alpha’s Quant Rating on Verve Therapeutics Historical earnings data for Verve Therapeutics Fin...

2024-03-26 11:43:00 ET More on CRISPR Technology Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT...

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medic...

2024-03-20 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-10 21:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-06 16:16:26 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi Begins Genetic Treatment IPO Rollout Moderna-backed Metagenomi sees stock fall 31% after $94M IPO Metagenomi prices initial off...